Therefore, compared to patients with LOXL1‐non‐mutant tumours, patients with LOXL1‐mutant tumours not only had a lower survival rate but also higher levels of transcripts of genes associated with biological processes, such as cell proliferation and immune activation. Here, LOXL1 is linked to neoplasm.